The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex

Pharmaceutical Research

Volumn 30, Issue 9, 2013, Pages 2344-2354

  Alaaeldin, Eman ^a,b   Abu Lila, Amr S ^a,c   Moriyoshi, Naoto ^a   Sarhan, Hatem A ^b   Ishida, Tatsuhiro ^a   Khaled, Khaled A ^b   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b MINIA UNIVERSITY   (Egypt)

^c ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

galctosidase; anti PEG IgM; cytokines; PEGylated siRNA cationic liposome (lipoplex); short interfering RNA (siRNA)

Indexed keywords

ANTINEOPLASTIC AGENT; DOUBLE STRANDED RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M ANTIBODY; LIPOPLEX; OXALIPLATIN; OXALIPLATIN PLUS SMALL INTERFERING RNA; SINGLE STRANDED RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENCAPSULATION; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSTIMULATION; LIPOSOMAL DELIVERY; MALE; MELTING POINT; MEMBRANE FLUIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; IMMUNOGLOBULIN M; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING;

EID: 84883283600     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1078-4     Document Type: Article

References (42)

1. Sibley CR, Seow Y, Wood MJ. Novel RNA-based strategies for therapeutic gene silencing. Mol Ther. 2010;18(3):466-76.
2. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 2002;3(10):737-47.
3. Bernstein E, Denli AM, Hannon GJ. The rest is silence. RNA. 2001;7(11):1509-21.
4. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003;4(6):457-67.
5. Aliabadi HM, Landry B, Sun C, Tang T, Uludag H. Supramolecular assemblies in functional siRNA delivery: where do we stand? Biomaterials. 2012;33(8):2546-69.
6. Singha K, Namgung R, Kim WJ. Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 2011;21(3):133-47.
7. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59(2-3):75-86.
8. Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006;13(9):819-29.
9. Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J. 2009;11(4):639-52.
10. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new Frontier in cancer chemotherapy. J Chemother. 2004;16 Suppl 4:94-7.
11. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999;86(1):72-8.
12. Roux E, Passirani C, Scheffold S, Benoit JP, Leroux JC. Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J Contr Release. 2004;94(2-3):447-51.
13. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23(4):457-62.
14. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526-9.
15. Lampson GP, Tytell AA, Field AK, Nemes MM, Hilleman MR. Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc Natl Acad Sci U S A. 1967;58(2):782-9.
16. Williams BR. Signal integration via PKR. Sci STKE. 2001;2001(89):re2.
17. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides. 2009;19(2):89-102.
18. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm. 2008;354(1-2):56-62.
19. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292(3):1071-9.
20. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Contr Release. 2006;112(1):15-25.
21. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomed (Lond). 2008;3(6):761-76.
22. Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection. J Contr Release. 2006;115(3):251-8.
23. Cui J, Li C, Wang C, Li Y, Zhang L, Yang H. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. J Pharm Pharmacol. 2008;60(12):1651-7.
24. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Contr Release. 2007;122(3):349-55.
25. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234(3):466-8.
26. Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Contr Release. 2009;137(3):234-40.
27. Hedman HK, Kirpekar F, Elmroth SK. Platinum interference with siRNA non-seed regions fine-tunes silencing capacity. J Am Chem Soc. 2011;133(31):11977-84.
28. Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Contr Release. 2011;151(2):149-54.
29. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11(3):263-70.
30. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996;93(7):2879-83.
31. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740-5.
32. Tel J, Hato SV, Torensma R, Buschow SI, Figdor CG, Lesterhuis WJ, et al. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother. 2012;61(7):1101-11.
33. Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother. 1994;48(10):445-53.
34. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593-604.
35. Kasparkova J, Vojtiskova M, Natile G, Brabec V. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chem. 2008;14(4):1330-41.
36. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol. 2005;348(5):1079-90.
37. Girart MV, Fuertes MB, Domaica CI, Rossi LE, Zwirner NW. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol. 2007;179(6):3472-9.
38. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298(2):607-12.
39. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1(3):297-315.
40. Kato T, Natsume A, Toda H, Iwamizu H, Sugita T, Hachisu R, et al. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 2010;17(11):1363-71.
41. Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther. 2011;19(11):2040-7.
42. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008;68(19):7975-84.